Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Accumulated Expenses: 2021-2025

Historic Accumulated Expenses for Prime Medicine (PRME) over the last 3 years, with Sep 2025 value amounting to $11.0 million.

  • Prime Medicine's Accumulated Expenses fell 41.13% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 41.13%. This contributed to the annual value of $15.9 million for FY2024, which is 12.71% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Accumulated Expenses is $11.0 million, which was down 9.52% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Accumulated Expenses registered a high of $37.2 million during Q4 2021, and its lowest value of $6.5 million during Q3 2022.
  • Moreover, its 3-year median value for Accumulated Expenses was $11.0 million (2025), whereas its average is $11.9 million.
  • In the last 5 years, Prime Medicine's Accumulated Expenses slumped by 71.26% in 2022 and then soared by 114.75% in 2023.
  • Over the past 5 years, Prime Medicine's Accumulated Expenses (Quarterly) stood at $37.2 million in 2021, then slumped by 71.26% to $10.7 million in 2022, then skyrocketed by 32.02% to $14.1 million in 2023, then increased by 12.71% to $15.9 million in 2024, then plummeted by 41.13% to $11.0 million in 2025.
  • Its Accumulated Expenses stands at $11.0 million for Q3 2025, versus $12.2 million for Q2 2025 and $9.2 million for Q1 2025.